Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells.
Curtarello M, Zulato E, Nardo G, Valtorta S, Guzzo G, Rossi E, Esposito G, Msaki A, Pastò A, Rasola A, Persano L, Ciccarese F, Bertorelle R, Todde S, Plebani M, Schroer H, Walenta S, Mueller-Klieser W, Amadori A, Moresco RM, Indraccolo S. Curtarello M, et al. Among authors: zulato e. Cancer Res. 2015 Jan 1;75(1):120-33. doi: 10.1158/0008-5472.CAN-13-2037. Epub 2014 Nov 7. Cancer Res. 2015. PMID: 25381153
Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.
Nardo G, Favaro E, Curtarello M, Moserle L, Zulato E, Persano L, Rossi E, Esposito G, Crescenzi M, Casanovas O, Sattler U, Mueller-Klieser W, Biesalski B, Thews O, Canese R, Iorio E, Zanovello P, Amadori A, Indraccolo S. Nardo G, et al. Among authors: zulato e. Cancer Res. 2011 Jun 15;71(12):4214-25. doi: 10.1158/0008-5472.CAN-11-0242. Epub 2011 May 5. Cancer Res. 2011. PMID: 21546569 Free article.
Metabolic effects of anti-angiogenic therapy in tumors.
Zulato E, Curtarello M, Nardo G, Indraccolo S. Zulato E, et al. Biochimie. 2012 Apr;94(4):925-31. doi: 10.1016/j.biochi.2012.01.001. Epub 2012 Jan 11. Biochimie. 2012. PMID: 22245704 Review.
LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab.
Bonanno L, De Paoli A, Zulato E, Esposito G, Calabrese F, Favaretto A, Santo A, Conte AD, Chilosi M, Oniga F, Sozzi G, Moro M, Ciccarese F, Nardo G, Bertorelle R, Candiotto C, De Salvo GL, Amadori A, Conte P, Indraccolo S. Bonanno L, et al. Among authors: zulato e. Clin Cancer Res. 2017 Jul 1;23(13):3316-3324. doi: 10.1158/1078-0432.CCR-16-2410. Epub 2017 Jan 24. Clin Cancer Res. 2017. PMID: 28119362 Clinical Trial.
LKB1 loss is associated with glutathione deficiency under oxidative stress and sensitivity of cancer cells to cytotoxic drugs and γ-irradiation.
Zulato E, Ciccarese F, Agnusdei V, Pinazza M, Nardo G, Iorio E, Curtarello M, Silic-Benussi M, Rossi E, Venturoli C, Panieri E, Santoro MM, Di Paolo V, Quintieri L, Ciminale V, Indraccolo S. Zulato E, et al. Biochem Pharmacol. 2018 Oct;156:479-490. doi: 10.1016/j.bcp.2018.09.019. Epub 2018 Sep 15. Biochem Pharmacol. 2018. PMID: 30222967
Metformin: a modulator of bevacizumab activity in cancer? A case report.
Indraccolo S, Randon G, Zulato E, Nardin M, Aliberti C, Pomerri F, Casarin A, Nicoletto MO. Indraccolo S, et al. Among authors: zulato e. Cancer Biol Ther. 2015;16(2):210-4. doi: 10.1080/15384047.2014.1002366. Cancer Biol Ther. 2015. PMID: 25607951 Free PMC article.
39 results